Want to see JP:4563 full AI Analyst Report?

AnGes (4563) Price & Analysis

1 Followers

4563 Stock Chart & Stats

¥47.00

¥0.00(0.00%)

At close: Jul 27 4:00 PM EDT

¥47.00

¥0.00(0.00%)

Day’s Range― - ―

52-Week Range¥44.00 - ¥120.00

Previous CloseN/A

Volume237.70K

Average Volume (3M)3.22M

Market Cap

¥18.75B

Enterprise Value¥18.05B

Total Cash (Recent Filing)¥835.88M

Total Debt (Recent Filing)¥688.34M

Price to Earnings (P/E)―

Beta0.56

Next Earnings

Aug 07, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-14.10

Shares Outstanding398,835,540

10 Day Avg. Volume1,701,110

30 Day Avg. Volume3,216,076

Financial Highlights & Ratios

PEG Ratio0.05

Price to Book (P/B)7.04

Price to Sales (P/S)24.76

P/FCF Ratio-3.75

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Accelerating Revenue GrowthSustained revenue acceleration indicates improving commercial traction or better partner monetization of the pipeline. Over 2-6 months this trend supports stronger external funding access, validates development progress to partners, and reduces single-period dependency on financing events.

Low Financial LeverageA low debt load provides durable financial flexibility for a biotech: it lowers fixed financing obligations and preserves capacity to absorb trial costs or pursue licensing deals. This reduces default risk and allows management to prioritize strategic R&D investments.

Licensing-driven Business ModelA collaboration and licensing model is capital-efficient and scalable long-term: milestone and royalty streams can bootstrap R&D, transfer late-stage development risk to partners, and create recurring, non-dilutive revenue as programs progress toward commercialization.

Bears Say

Persistent Negative Cash FlowChronically negative operating and free cash flow creates ongoing funding dependency. Over multiple quarters this elevates dilution or covenant risk, constrains the ability to self-fund trials, and forces timing-sensitive partnership or financing decisions that can impair strategic flexibility.

Large Operating LossesSustained operating losses mean the business remains unprofitable and reliant on external capital or partner milestones. This structural profitability gap limits reinvestment capacity, stresses margins absent product commercialization, and increases execution risk over the medium term.

Eroding Balance Sheet Equity/assetsShrinking assets and equity reflect cumulative cash burn and weaken collateral or solvency metrics. Over months this deterioration raises funding cost, reduces negotiating leverage with partners or lenders, and increases the probability of dilutive financing to sustain operations.

4563 FAQ

What was AnGes Inc’s price range in the past 12 months?

AnGes Inc lowest stock price was ¥44.00 and its highest was ¥120.00 in the past 12 months.

What is AnGes Inc’s market cap?

AnGes Inc’s market cap is ¥18.75B.

When is AnGes Inc’s upcoming earnings report date?

AnGes Inc’s upcoming earnings report date is Aug 07, 2026 which is in 5 days.

How were AnGes Inc’s earnings last quarter?

AnGes Inc released its earnings results on May 08, 2026. The company reported -¥2.74 earnings per share for the quarter, missing the consensus estimate of N/A by -¥2.74.

Is AnGes Inc overvalued?

According to Wall Street analysts AnGes Inc’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does AnGes Inc pay dividends?

AnGes Inc does not currently pay dividends.

What is AnGes Inc’s EPS estimate?

AnGes Inc’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does AnGes Inc have?

AnGes Inc has 398,835,540 shares outstanding.

What happened to AnGes Inc’s price movement after its last earnings report?

AnGes Inc reported an EPS of -¥2.74 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 1.923%.

Which hedge fund is a major shareholder of AnGes Inc?

Currently, no hedge funds are holding shares in JP:4563

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

AnGes Inc

AnGes, Inc. (4563) is a Japanese biotechnology company focused on developing and commercializing nucleic-acid–based medicines and gene therapies. The company’s activities center on research and development, clinical development, regulatory work, and potential out-licensing of drug candidates, with a portfolio historically associated with DNA plasmid–based therapeutics and other genetic medicine approaches. null